Modafinil vs Selank
FDA Approved vs Well Studied
compatible Researched · 90% Balanced anxiety reduction and wakefulness.
Molecular Data
Modafinil Selank
Weight 273.35 Da 751.89 Da
Half-life ~12-15 hours 2-10 minutes
Chain — 7 amino acids
Type Diphenylmethylsulfinylacetamide (C15H15NO2S) Tuftsin analog
Key Benefits
Modafinil
01 Sustained wakefulness and alertness for 10-15 hours without the jitteriness of traditional stimulants
02 Enhanced executive function, working memory, and decision-making under fatigue
03 Improved focus and concentration during prolonged cognitive tasks
04 Reduced impulsivity and improved task completion in sleep-deprived individuals
05 Low abuse potential relative to amphetamine-class stimulants (Schedule IV)
06 Minimal impact on normal sleep architecture when taken in the morning
Selank
01 Rapid onset anxiolytic effects
02 Enhanced BDNF expression (30% increase)
03 Improved stress resilience
04 Cognitive enhancement
05 Immune modulation
06 No tolerance or withdrawal
07 Neuroprotective effects
Dosing Protocols
Modafinil
100-200 mg/day / Once daily (morning)
Selank
250-500mcg per dose / 1-2x daily (morning and/or evening)
Mild anxiety relief 250mcg 1x daily
Moderate anxiety/cognitive 250mcg 2x daily (morning & evening)
Intensive anxiety support 500mcg 1x daily (divided doses)
Cognitive enhancement 250-350mcg 1x daily (morning)
PTSD support 250mcg 2x daily
Immune support 250mcg 1x daily for 2-4 weeks
Side Effects
Modafinil
Headache (most frequently reported side effect, often dose-dependent)
Insomnia (particularly if taken too late in the day)
Anxiety and nervousness
Appetite suppression and mild nausea
Dry mouth
Dizziness
Gastrointestinal discomfort (diarrhea, abdominal pain)
Selank
Minimal side effects - excellent safety profile
No sedation or cognitive impairment
No tolerance, dependence, or withdrawal
Contraindications
Known hypersensitivity to modafinil or armodafinil
History of Stevens-Johnson Syndrome, TEN, or DRESS with prior modafinil/armodafinil use
Severe hepatic impairment (dose reduction required in moderate impairment)
Unstable angina or recent myocardial infarction
Left ventricular hypertrophy or clinically significant mitral valve prolapse with prior stimulant use
Pregnancy (limited human data; animal studies show teratogenicity at high doses)
Known peptide allergies
Pregnancy or breastfeeding
Consult healthcare provider with multiple psychiatric medications
Research Evidence
Modafinil Selank
Status FDA Approved Well Studied
References 5 studies 5 studies
Latest — 2020
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.